Project Grant 2321818
Award Date
2/1/24
Completion Date
1/31/25
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94112, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $1,000,000 to Theromics Inc., a minority-owned small disadvantaged business, aims to develop a novel protein-based gel to improve the effectiveness and safety of thermal tumor ablation procedures. The project will involve creating a computational model to predict the thermal behavior of the gel, conducting preclinical studies to quantify temperatures, ablation zone size,...
The National Science Foundation awarded a $255,731 Small Business Innovation Research Phase I Project Grant to Senoguard Inc. under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant funds the development and preclinical testing of a novel cryoablation probe system for post-lumpectomy margin ablation cancer treatment. Specifically, the company will design and optimize the probe for optimal contact and thermal transfer with tumor cells in fixed in vitro testing. The...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $999,545 to Senoguard Inc., a woman-owned small business located in Seal Beach, CA, is supporting the development and testing of a novel minimally invasive cryogenic probe for post-lumpectomy margin ablation treatment. The project aims to complete engineering and validation activities for this cryoablation probe, which will be coupled with an external cryoagent controller,...
This SBIR Phase I grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) is for the development of an advanced wound care product to treat diabetic foot ulcers. Therapeutic Bandage Products, Inc. will receive $305,000 to develop a patented microneedle bandage that delivers three therapeutic agents to disinfect the wound, prevent biofilm formation, and activate the immune system. This innovative product has significant...
This Project Grant award, valued at $275,000, was provided by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084). The award was granted to Islex Therapeutics, LLC, a minority-owned small business located in Baltimore, Maryland, to develop a novel therapeutic product for the treatment of stage 3 type 1 diabetes (T1D) and other forms of severe beta-cell loss. The project aims to harness the synergistic effects of autoimmune...
This SBIR Phase I award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Om Therapeutics Inc. to develop a novel methodology for the scalable, empirical generation of small molecule and protein interaction data. The goal is to enable accelerated drug discovery through advanced machine learning models that can predict new therapeutic interactions. The project aims to encapsulate proteins and small molecules in...
The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to Current Surgical Inc. from May 15, 2021 to November 30, 2021 under the Engineering program (CFDA 47.041). The grant funds the development of a smart needle for precise tumor ablation. The NSF Engineering program supports innovation, creativity, and excellence in engineering research and education to improve quality of life and economic strength. This award advances those goals by...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $1,000,000 aims to demonstrate the safety and tolerability of a novel "living pharmacy" organism as a treatment for diabetes and obesity in cats. The project plans to show that a single injection can control blood glucose and weight gain for 12 weeks or longer, with the eventual goal of entering the human market. The award was made to Simmbion LLC, a small...
This $999,783 Phase II Small Business Innovation Research (SBIR) cooperative agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Intact Therapeutics' development of a thermogel-based drug delivery platform for the treatment of upper gastrointestinal bleeding (UGIB). Intact Therapeutics' proprietary thermogel technology aims to rapidly stop UGIB prior to endoscopic treatment, potentially reducing patient morbidity,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) Program (CFDA 47.084) Project Grant award of $275,000 provides funding to Illuminate Therapeutics, Inc. to develop their Light Activated Drug Delivery and Release (LADDR) platform technology. The objective is to improve patient outcomes in the treatment of head and neck and esophageal cancers, which represent a combined market of over $2.34B in 2021 growing at 10.5% annually. The key focus of this SBIR Phase...